DIABLO

DIABLO — Direct IAP-Binding Protein with Low pI (SMAC)

Introduction

```mermaid
flowchart TD
classDef gene fill:#0a1f0a,stroke:#4caf50
classDef protein fill:#0a1929,stroke:#2196f3
classDef disease fill:#2d0f0f,stroke:#e91e63
classDef pathway fill:#3e2200,stroke:#ff9800
classDef mechanism fill:#1a0a1f,stroke:#9c27b0
classDef therapeutic fill:#e0f2f1,stroke:#009688
DIABLO["DIABLO"] -->|"implicated_in"| neurodegeneration["neurodegeneration"]
DIABLO["DIABLO"] ==>|"activates"| APOPTOSIS["APOPTOSIS"]
DIABLO["DIABLO"] ==>|"activates"| AUTOPHAGY["AUTOPHAGY"]
DIABLO["DIABLO"] ==>|"activates"| HTRA2["HTRA2"]
DIABLO["DIABLO"] -->|"interacts_with"| SMAC["SMAC"]
DIABLO["DIABLO"] ==>|"activates"| LC3["LC3"]
DIABLO["DIABLO"] ==>|"activates"| Als["Als"]
DIABLO["DIABLO"] -->|"interacts_with"| Ms["Ms"]
DIABLO["DIABLO"] ==>|"activates"| Apoptosis["Apoptosis"]
DIABLO["DIABLO"] ==>|"activates"| Autophagy["Autophagy"]
DIABLO["DIABLO"] -->|"regulates"| EGF["EGF"]
DIABLO["DIABLO"] -->|"regulates"| ERK1["ERK1"]
DIABLO["DIABLO"] -->|"regulates"| APOPTOSIS["APOPTOSIS"]
DIABLO["DIABLO"] -->|"regulates"| MDM2["MDM2"]
DIABLO["DIABLO"] -->|"regulates"| RAF1["RAF1"]
DIABLO["DIABLO"] -->|"regulates"| P38["P38"]
DIABLO["DIABLO"] -->|"regulates"| DYRK1A["DYRK1A"]
DIABLO["DIABLO"] -->|"regulates"| SMAC["SMAC"]
DIABLO["DIABLO"] -->|"regulates"| AIF["AIF"]
DIABLO["DIABLO"] -->|"regulates"| Ms["Ms"]
DIABLO["DIABLO"] -->|"regulates"| Stroke["Stroke"]
DIABLO["DIABLO"] -->|"regulates"| Neurodegenerat

DIABLO — Direct IAP-Binding Protein with Low pI (SMAC)

Introduction

DIABLO (Direct IAP-Binding Protein with Low pI), also known as SMAC (Second Mitochondria-Derived Activator of Caspases), is a mitochondrial protein that plays a critical role in regulating [apoptosis](/entities/apoptosis) through its interactions with Inhibitor of Apoptosis Proteins (IAPs). First characterized in 2000 by Du et al., SMAC/DIABLO is released from the mitochondrial intermembrane space during the early stages of programmed cell death, where it functions as a potent pro-apoptotic molecule by neutralizing IAP-mediated caspase inhibition [@du2000].

In the context of neurodegenerative diseases, SMAC/DIABLO has emerged as a key player in the death of [neurons](/entities/neurons) in both [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease). The protein's dual role—as both a mediator of pathological cell death and a potential therapeutic target—has made it the subject of extensive research over the past two decades [@martinezruiz2005].

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Second Mitochondria-Derived Activator of Caspases (SMAC)</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>DIABLO</td></tr>
<tr><td><strong>Full Name</strong></td><td>Direct IAP-Binding Protein with Low pI</td></tr>
<tr><td><strong>Chromosome</strong></td><td>12q24.31</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[56616](https://www.ncbi.nlm.nih.gov/gene/56616)</td></tr>
<tr><td><strong>OMIM</strong></td><td>604476</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000140297</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q9NR28](https://www.uniprot.org/uniprot/Q9NR28)</td></tr>
<tr><td><strong>Protein Length</strong></td><td>239 amino acids</td></tr>
<tr><td><strong>Cellular Location</strong></td><td>Mitochondria (intermembrane space)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Cancer</td></tr>
</table>
</div>

Gene Structure and Evolution

The DIABLO gene spans approximately 5.5 kb on chromosome 12q24.31 and consists of 6 exons encoding a 239-amino-acid precursor protein. The gene is evolutionarily conserved across vertebrates, with orthologs identified in mice, rats, zebrafish, and other model organisms. The N-terminal 55 amino acids encode a mitochondrial targeting sequence (MTS) that directs the protein to the mitochondrial intermembrane space, followed by a functional domain that binds IAP proteins.

Phylogenetic analysis reveals that DIABLO belongs to a family of mitochondrial pro-apoptotic proteins that includes OMI/HtrA2, which shares functional similarity in its ability to neutralize IAPs. However, DIABLO and OMI/HtrA2 differ in their mechanism of release from mitochondria and their specific IAP binding profiles.

Protein Structure and Function

Structural Features

SMAC/DIABLO is synthesized as a 239-amino-acid precursor with an N-terminal mitochondrial targeting sequence (residues 1-55) that is cleaved upon import into the mitochondrial intermembrane space, generating the mature 184-amino-acid active form [@du2000]. The mature protein forms a homodimer, with each monomer adopting an extended barrel-like structure. The critical IAP-binding motif is located at the N-terminus (residues 56-59: Ala-Val-Pro-Ile in the mature protein), which mimics the IBM (IAP-binding motif) found in other pro-apoptotic proteins.

The dimeric structure of SMAC/DIABLO is essential for its function, as the dimer interface creates a binding surface that engages multiple BIR (baculovirus IAP repeat) domains simultaneously, providing high-affinity interaction with IAP proteins such as XIAP, cIAP1, and cIAP2.

Mechanism of Action

The primary function of SMAC/DIABLO is to promote [caspase](/entities/caspase) activation by antagonizing IAP proteins. Under normal cellular conditions, SMAC/DIABLO resides in the mitochondrial intermembrane space and has no pro-apoptotic activity. However, upontriggering of the intrinsic (mitochondrial) apoptosis pathway, SMAC/DIABLO is released into the cytosol through the mitochondrial outer membrane permeabilization (MOMP) channel [@du2000].

Once in the cytosol, SMAC/DIABLO binds to IAP proteins through its N-terminal IBM motif, displacing caspases from IAP-mediated inhibition. The key targets include:

By neutralizing these IAPs, SMAC/DIABLO removes the brake on caspase activation and enables efficient execution of [apoptosis](/entities/apoptosis) [@fulda2002].

Relationship to Other Apoptotic Proteins

SMAC/DIABLO operates in parallel with cytochrome c in the apoptotic cascade. Both are released from mitochondria upon MOMP, but they target different components of the apoptotic machinery:

• Cytochrome c binds to Apaf-1, forming the apoptosome that activates [caspase-9](/genes/casp9)
• SMAC/DIABLO removes IAP inhibition, allowing caspases to remain active

Expression Pattern and Regulation

Tissue Distribution

SMAC/DIABLO is expressed in most human tissues, with highest expression in testis, heart, brain, and skeletal muscle. In the brain, expression is detected in both [neurons](/entities/neurons) and glia, with particular abundance in the hippocampus, cortex, and basal ganglia—regions affected in neurodegenerative diseases.

Transcriptional Regulation

The DIABLO gene is transcriptionally regulated by several factors:

• p53: The tumor suppressor p53 can activate DIABLO transcription as part of its pro-apoptotic program
• FOXO transcription factors: Regulate DIABLO expression in response to oxidative stress
• NF-κB: Can repress DIABLO expression as an anti-apoptotic mechanism

Post-translational Regulation

SMAC/DIABLO activity is regulated at multiple levels:

• Mitochondrial import: Dependent on mitochondrial membrane potential
• Proteolytic processing: The N-terminal targeting sequence is cleaved by mitochondrial processing peptidases
• Oligomerization: Dimer formation is required for full activity

Role in Alzheimer's Disease

Alzheimer's disease (AD) is characterized by progressive neuronal loss in the hippocampus and cortex, with apoptosis being a major mechanism of neuronal death. SMAC/DIABLO has been implicated in multiple aspects of AD pathogenesis.

Amyloid-Beta-Induced SMAC Release

In AD, accumulation of [amyloid-beta](/proteins/amyloid-beta) (Aβ) peptides triggers mitochondrial dysfunction and promotes SMAC/DIABLO release from mitochondria. Studies have demonstrated that Aβ treatment of neurons leads to rapid release of SMAC/DIABLO into the cytosol, preceding caspase activation and cell death [@gates2008].

The mechanism involves:

Interaction with Tau Pathology

Recent research has revealed a connection between SMAC/DIABLO and [tau](/proteins/tau-protein) pathology in AD. Tau pathology promotes mitochondrial dysfunction and enhances SMAC/DIABLO release, while SMAC/DIABLO can in turn accelerate tau phosphorylation through caspase-dependent pathways [@wang2024].

Therapeutic Implications

The SMAC/IAP axis represents a promising therapeutic target in AD:

• SMAC mimetics: Small molecules that mimic SMAC/DIABLO function have shown neuroprotective effects in AD models by promoting IAP degradation and paradoxically enhancing pro-survival signaling
• IAP antagonists: While initially designed for cancer, these compounds may have utility in modulating neuronal survival in AD
• Combination approaches: Targeting both SMAC/IAP and other pathways (e.g., amyloid, tau) may provide synergistic benefits [@moran2010]

Role in Parkinson's Disease

Parkinson's disease (PD) is characterized by progressive loss of dopaminergic neurons in the substantia nigra. Mitochondrial dysfunction is a central feature of PD pathogenesis, and SMAC/DIABLO plays a critical role in dopaminergic neuron death.

Mitochondrial Dysfunction in PD

Multiple genetic and environmental factors linked to PD affect mitochondrial function:

• LRRK2 mutations: Associated with altered mitochondrial dynamics and increased susceptibility to apoptosis
• GBA mutations: Associated with impaired mitochondrial function and enhanced SMAC/DIABLO release
• Parkin mutations: Impair mitophagy, leading to accumulation of dysfunctional mitochondria
• PINK1 mutations: Disrupt mitochondrial quality control mechanisms

Alpha-Synuclein and SMAC/DIABLO

The aggregation of [alpha-synuclein](/proteins/alpha-synuclein) (α-syn), a hallmark of PD, is linked to mitochondrial dysfunction and SMAC/DIABLO release. α-syn can:

• Directly interact with mitochondrial membranes, promoting MOMP
• Induce BAX translocation to mitochondria
• Enhance SMAC/DIABLO release and subsequent apoptosis

Neuroprotective Strategies

Targeting the SMAC/IAP pathway in PD offers several therapeutic opportunities:

• Inhibiting SMAC release: Preventing mitochondrial permeabilization
• IAP overexpression: Enhancing endogenous anti-apoptotic mechanisms
• Caspase inhibition: Blocking the downstream effects of SMAC/DIABLO release [@burke2017]

Role in Other Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis (ALS)

SMAC/DIABLO has been implicated in motor neuron death in ALS. Mutations in SOD1, TDP-43, and C9orf72 repeat expansions all lead to mitochondrial dysfunction and enhanced SMAC/DIABLO release. Studies in ALS models show that:

• SMAC/DIABLO release precedes motor neuron death
• IAP levels are decreased in ALS spinal cord
• Caspase activation is elevated in affected neurons

Huntington's Disease

In Huntington's disease (HD), mutant huntingtin protein promotes mitochondrial dysfunction and SMAC/DIABLO release. The SMAC/IAP pathway contributes to the selective vulnerability of striatal neurons in HD.

Multiple Sclerosis

Although primarily an autoimmune demyelinating disease, axonal loss in MS involves apoptotic mechanisms with SMAC/DIABLO playing a role in neuronal degeneration.

Interaction with Neuroinflammation

Neuroinflammation is a common feature of neurodegenerative diseases, and SMAC/DIABLO has been implicated in the inflammatory response [@zhang2020]:

• Inflammasome activation: SMAC/DIABLO can promote NLRP3 inflammasome activation
• Microglial activation: Release of mitochondrial DAMPs including SMAC/DIABLO can activate microglia
• Cytokine release: SMAC/DIABLO-induced caspase activation can promote pro-inflammatory cytokine processing

The IAP Family and Neuronal Survival

The Inhibitor of Apoptosis Proteins (IAPs) are a family of anti-apoptotic proteins that play crucial roles in neuronal survival. The major neuronal IAPs include:

| IAP | Gene | Function in Neurons |
|-----|------|---------------------|
| XIAP | XIAP | Inhibits caspases 3, 7, 9; highly expressed in neurons |
| cIAP1 | BIRC2 | Regulates NF-κB signaling; protects against TNF-α toxicity |
| cIAP2 | BIRC3 | Similar to cIAP1; role in microglial survival |
| Survivin | BIRC5 | Cell cycle regulation; low in mature neurons |

The balance between pro-apoptotic molecules (like SMAC/DIABLO) and IAPs determines neuronal fate. In neurodegenerative diseases, this balance shifts toward apoptosis due to increased SMAC/DIABLO release and/or decreased IAP function [@chen2019].

Therapeutic Targeting

SMAC Mimetics

SMAC mimetics (also called IAP antagonists) are small molecules that mimic the IAP-binding function of SMAC/DIABLO. Several generations have been developed:

In neurodegenerative disease models, SMAC mimetics have shown complex effects—sometimes protective, sometimes detrimental—depending on the context and disease stage.

Challenges and Opportunities

Therapeutic targeting of the SMAC/IAP axis in neurodegeneration presents challenges:

• Timing: Inhibition may be beneficial in early disease but harmful in late stages
• Cell-type specificity: Targeting specific neuronal populations
• Blood-brain barrier penetration: Drug delivery to the CNS
• Combination therapy: Synergy with other disease-modifying approaches [@yang2022]

Mitochondrial Quality Control and SMAC/DIABLO

The release of SMAC/DIABLO from mitochondria is closely linked to mitochondrial quality control mechanisms. Mitophagy—the selective autophagy of damaged mitochondria—can prevent SMAC/DIABLO release by eliminating compromised mitochondria before MOMP occurs [@liu2021].

In neurodegenerative diseases, mitophagy is often impaired, leading to accumulation of dysfunctional mitochondria that are more prone to release SMAC/DIABLO. Key regulators include:

• PINK1/Parkin pathway: Impaired in familial PD
• BNIP3/NIX receptors: Regulate mitophagy in neurons
• OPTN: Autophagy receptor for damaged mitochondria

Interaction with Other Cell Death Pathways

While apoptosis is the primary cell death pathway influenced by SMAC/DIABLO, it can also intersect with other cell death modalities:

• Necroptosis: SMAC/DIABLO can promote necroptosis through IAP degradation
• Pyroptosis: Caspase-1 activation may be influenced by IAP levels
• Ferroptosis: The relationship with iron-dependent cell death is being explored
• Autophagy-dependent cell death: SMAC/DIABLO release can be both cause and consequence of autophagy dysregulation

Biomarker Potential

SMAC/DIABLO and its fragments have potential as biomarkers in neurodegenerative diseases:

• CSF SMAC levels: Elevated in some AD and PD patients
• Mitochondrial SMAC: Reduced in affected brain regions
• IAP levels in blood: Correlate with disease progression in some studies

Animal Models

Several animal models have been used to study SMAC/DIABLO in neurodegeneration:

• Smac/DIABLO knockout mice: Viable but more susceptible to apoptotic stimuli
• Transgenic AD models: Show enhanced SMAC release with disease progression
• PD models: MPTP and 6-OHDA models demonstrate SMAC/DIABLO involvement
• Conditional knockout models: Tissue-specific deletion to study neuronal effects

Future Directions

Research on SMAC/DIABLO in neurodegeneration continues to evolve:

• Single-cell analysis: Understanding cell-type-specific roles
• Spatiotemporal resolution: Tracking SMAC release in real time
• Novel therapeutics: Next-generation IAP modulators with neuroprotective properties
• Biomarker development: Clinical utility of SMAC measurements
• Gene therapy: Targeted delivery of IAP genes to neurons

See Also

• [Apoptosis Pathways](/mechanisms/apoptosis-neuronal)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [XIAP](/genes/xiap)
• [CASP3](/genes/casp3)
• [CASP9](/genes/casp9)
• [Mitochondrial Apoptosis Pathway](/mechanisms/mitochondrial-apoptosis)
• [Neuroinflammation](/mechanisms/neuroinflammation-pathways)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving DIABLO discovered through SciDEX knowledge graph analysis: